SCHEDULE 13D/A: Major Shareholder Heng Fai Ambrose Chan Increases Stake in DSS, Inc. to 67.6% Following Recent Stock Grant and Purchases

Heng Fai Ambrose Chan and affiliated entities have significantly increased their beneficial ownership in DSS, Inc. to 67.6% of outstanding common stock through a recent stock grant and direct share purchases.

Summary

• Heng Fai Ambrose Chan and his affiliated entities (Heng Fai Holdings Limited, Alset Inc., Global Biomedical Pte. Ltd., and Alset International Limited) collectively beneficially own 6,148,664 shares of DSS, Inc. common stock.
• This represents 67.6% of the 9,092,518 shares of common stock outstanding as of February 6, 2025.
• On February 6, 2025, Mr. Chan, through his personally owned company Heng Fai Holdings Limited, was awarded a stock grant of 1,000,000 newly issued shares of DSS, Inc. common stock pursuant to the Issuer's 2020 Employee, Director and Consultant Equity Incentive Plan.
• Prior to this, on December 10, 2024, Alset Inc. entered into a stock purchase agreement with the Issuer to acquire 820,597 newly issued shares of DSS, Inc. common stock for a purchase price of $0.9749 per share.
• Also on December 10, 2024, Mr. Chan directly entered into a stock purchase agreement with the Issuer to acquire 205,149 newly issued shares of DSS, Inc. common stock for a purchase price of $0.9749 per share.

Sentiment

Score: 7

Explanation: The increased stake by a major insider and affiliated entities, including a stock grant and direct purchases, generally indicates strong confidence and alignment of interests, which is positive. However, the high concentration of ownership could be a concern for minority shareholders.

Positives

• Increased insider ownership by a key executive (Heng Fai Ambrose Chan) and affiliated entities, signaling strong confidence in the company's future.
• The stock grant to Mr. Chan aligns management incentives with shareholder interests.
• Recent share purchases by Alset Inc. and Mr. Chan at a specific price ($0.9749 per share) indicate a valuation point considered attractive by significant shareholders.

Negatives

• The significant concentration of ownership (67.6% by one individual and related entities) could reduce liquidity for other shareholders and potentially limit the influence of minority shareholders.
• The issuance of new shares for the stock grant and purchases could lead to dilution for existing shareholders, although the specific impact depends on the total shares outstanding before these transactions.

Risks

• High concentration of ownership by a single individual and related entities may lead to reduced market liquidity and potential governance concerns for minority shareholders.
• Future dilution risk from additional equity issuances, such as further grants under the 2020 Employee, Director and Consultant Equity Incentive Plan.

Future Outlook

The document does not provide explicit forward-looking statements or guidance beyond the details of the stock grant and purchases, which reflect ongoing investment and alignment of interests by a major shareholder.

Industry Context

This Schedule 13D filing primarily details changes in beneficial ownership by a significant insider and related entities. It reflects an internal corporate action (stock grant) and strategic investments by a major shareholder, rather than broader industry trends. The increased stake by Heng Fai Ambrose Chan, who is also Chairman and CEO of Alset International Limited, suggests a continued commitment to DSS, Inc. within his broader investment portfolio.

Comparison to Industry Standards

• This filing is a standard Schedule 13D amendment reporting changes in beneficial ownership.
• The concentration of ownership at 67.6% by a single individual and related entities is high, which is common in companies with a strong controlling shareholder or founder. For comparison, companies like Berkshire Hathaway (controlled by Warren Buffett) or Meta Platforms (controlled by Mark Zuckerberg) also exhibit high insider control, which can provide stability but also raise questions about minority shareholder influence.
• The share purchase price of $0.9749 per share provides a recent valuation point for these specific transactions, but without broader market context or comparable company valuations, a detailed assessment against industry standards is not possible from this document alone.

Related Party Transactions

• The stock grant of 1,000,000 newly issued shares to Heng Fai Ambrose Chan (through Heng Fai Holdings Limited) is a transaction between the Issuer and a controlling shareholder/executive.
• The purchase of 820,597 newly issued shares by Alset Inc. and 205,149 newly issued shares by Mr. Chan directly are also transactions between the Issuer and related parties, given Mr. Chan's control over Alset Inc. and Alset International Limited.

Stakeholder Impact

• Shareholders: Increased insider ownership may be viewed positively as a sign of confidence, but the high concentration of ownership could reduce liquidity and influence for minority shareholders. Dilution from newly issued shares is also a factor.
• Management/Employees: The stock grant to Mr. Chan aligns his incentives with the company's performance.

Next Steps

• The document does not explicitly state future actions or milestones beyond the reporting of past transactions.

Key Dates

Recommendation

Keywords

DSS Inc., Schedule 13D, Beneficial Ownership, Heng Fai Ambrose Chan, Alset Inc., Stock Grant, Share Purchase, Insider Ownership, Equity Incentive Plan, Common Stock, SEC Filing, Corporate Governance